Literature DB >> 3907678

Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis.

R C Butler, D H Goddard, C S Higgens, P Hollingworth, C T Pease, M A Stodell, J T Scott.   

Abstract

Flurbiprofen has been compared with phenylbutazone in a double-blind study involving 33 patients with acute gout. Patients received either flurbiprofen 400 mg daily for 48 h followed by 200 mg daily, or phenylbutazone 800 mg daily for 48 h followed by 400 mg daily. The drugs were of comparable efficacy, while side-effects were uncommon and relatively mild. Flurbiprofen appears to be a satisfactory alternative to phenylbutazone in the management of acute gouty arthritis.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3907678      PMCID： PMC1400723          DOI： 10.1111/j.1365-2125.1985.tb05110.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  10 in total

1.  Gout in the time and person of George IV: a case history.

Authors:  E G BYWATERS
Journal:  Ann Rheum Dis       Date:  1962-12       Impact factor: 19.103

2.  208.--INDOMETHACIN IN THE TREATMENT OF ACUTE GOUT.

Authors:  P L BOARDMAN; F HARTDUDLEY
Journal:  Practitioner       Date:  1965-04

3.  Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis.

Authors:  G I Weiner; S R White; R I Weitzner; H M Rubinstein
Journal:  Arthritis Rheum       Date:  1979-04

4.  Comparison of indomethacin and phenylbutazone in acute gout.

Authors:  C J Smyth; J S Percy
Journal:  Ann Rheum Dis       Date:  1973-07       Impact factor: 19.103

5.  [Treatment of gout].

Authors:  J P Camus; A Prier; C Merlet; A C Koeger
Journal:  Rev Prat       Date:  1983-10-01

6.  [Double-blind trial: ketoprofen versus phenylbutazone in acute gouty arthritis (author's transl)].

Authors:  W Siegmeth; P Placheta
Journal:  Wien Klin Wochenschr       Date:  1976-09-03       Impact factor: 1.704

7.  Introduction to sample size determination and power analysis for clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1981-06

8.  Treatment of primary gout: the present status.

Authors:  A B Gutman
Journal:  Arthritis Rheum       Date:  1965-10

9.  Double-blind trial of feprazone and phenylbutazone in acute gout.

Authors:  J A Reardon; A Stockman; L G Darlington; J T Scott
Journal:  Curr Med Res Opin       Date:  1980       Impact factor: 2.580

10.  Multicentre trial of naproxen and phenylbutazone in acute gout.

Authors:  R A Sturge; J T Scott; E B Hamilton; S P Liyanage; A S Dixon; J Davies; C Engler
Journal:  Ann Rheum Dis       Date:  1977-02       Impact factor: 19.103
  10 in total
  6 in total

Review 1.  Diagnosis and management of gout: a rational approach.

Authors:  E Suresh
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

Review 2.  Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?

Authors:  Ted R Mikuls; Kenneth G Saag
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

Review 3.  [Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)].

Authors:  U Kiltz; R Alten; M Fleck; K Krüger; B Manger; U Müller-Ladner; H Nüßlein; M Reuss-Borst; A Schwarting; H Schulze-Koops; A Tausche; J Braun
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

Review 4.  Optimizing current treatment of gout.

Authors:  Frances Rees; Michelle Hui; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2014-03-11       Impact factor: 20.543

Review 5.  Non-steroidal anti-inflammatory drugs for acute gout.

Authors:  Caroline Mpg van Durme; Mihir D Wechalekar; Robert Bm Landewé; Jordi Pardo Pardo; Sheila Cyril; Désirée van der Heijde; Rachelle Buchbinder
Journal:  Cochrane Database Syst Rev       Date:  2021-12-09

6.  Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.

Authors:  Francisca Sivera; Mariano Andrés; Loreto Carmona; Alison S R Kydd; John Moi; Rakhi Seth; Melonie Sriranganathan; Caroline van Durme; Irene van Echteld; Ophir Vinik; Mihir D Wechalekar; Daniel Aletaha; Claire Bombardier; Rachelle Buchbinder; Christopher J Edwards; Robert B Landewé; Johannes W Bijlsma; Jaime C Branco; Rubén Burgos-Vargas; Anca I Catrina; Dirk Elewaut; Antonio J L Ferrari; Patrick Kiely; Burkhard F Leeb; Carlomaurizio Montecucco; Ulf Müller-Ladner; Mikkel Ostergaard; Jane Zochling; Louise Falzon; Désirée M van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-07-18       Impact factor: 19.103
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.